PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...
No new safety issues related to PGN-EDO51 have been observed since the Company’s last safety update as of January 23, 2025. “With our 10 mg/kg cohort of CONNECT1 study fully enrolled and data ...
Recent Program Updates PGN-EDODM1: Myotonic Dystrophy Type 1 (DM1) PGN-EDO51: Duchenne Muscular Dystrophy (DMD) The 10 mg/kg cohort is fully enrolled (n=4) and participants in the 5 mg/kg cohort ...
PepGen has previously faced an FDA clinical hold on the investigational new drug application of PGN-ENO51 in the Phase II ...
PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. This release discusses PGN-EDO51 and PGN-EDODM1, investigational therapies ...
PepGen (PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne ...
PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. This release discusses PGN-EDO51 and PGN-EDODM1, investigational therapies ...
PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...
"Today, we reported initial results from FREEDOM-DM1, which showed robust splicing correction in patients with DM1 following a single dose of PGN-EDODM1. We believe these data contribute to the ...
Hosted on MSN19d
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz?Stifel also noted a "highly promising signal on splicing" and saw an improved probability of success for PGN-EDODM1 ... 84% in the past 12 months. For updates and corrections, email newsroom ...
Stocktwits on MSN16d
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last WeekAIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback